1. Home
  2. WFG vs ERAS Comparison

WFG vs ERAS Comparison

Compare WFG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Fraser Timber Co. Ltd.

WFG

West Fraser Timber Co. Ltd.

HOLD

Current Price

$69.68

Market Cap

5.0B

Sector

N/A

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$18.34

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WFG
ERAS
Founded
1955
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.0B
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
WFG
ERAS
Price
$69.68
$18.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
12
Target Price
$89.50
$14.25
AVG Volume (30 Days)
212.6K
4.3M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
2.03%
N/A
EPS Growth
N/A
36.23
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.05
N/A
Revenue Next Year
$10.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$57.34
$1.33
52 Week High
$76.99
$24.28

Technical Indicators

Market Signals
Indicator
WFG
ERAS
Relative Strength Index (RSI) 58.20 N/A
Support Level $63.81 N/A
Resistance Level $72.72 N/A
Average True Range (ATR) 2.37 0.00
MACD 0.36 0.00
Stochastic Oscillator 98.55 0.00

Price Performance

Historical Comparison
WFG
ERAS

About WFG West Fraser Timber Co. Ltd.

West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: